{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:54:39Z","timestamp":1793361279574,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Disease","doi-asserted-by":"crossref","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Disease","doi-asserted-by":"crossref","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>We present information on the burden of vaccine-preventable diseases in people with rheumatoid arthritis (RA), the latest evidence on vaccine immunogenicity in disease-modifying antirheumatic drug (DMARD) users, and expert and guideline-based immunization recommendations. We focus on infections with the highest morbidity and mortality, and those relevant due to new developments or current outbreaks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Following the license expansion for two respiratory syncytial virus (RSV) vaccines, GSK\u2019s Arexvy and Pfizer\u2019s Abrysvo, the Advisory Committee for Immunization Practices (ACIP) expanded the recommendation for vaccination in adults at increased risk of severe RSV disease. In the spring of 2025, the Center for Disease Control lowered the cutoff for immunization in high-risk groups from \u2265\u200960 to \u2265\u200950 years. There are new 2024\u20132025 SARS-CoV-2 vaccines and updated ACIP recommendations for SARS-CoV-2 immunization that address new viral strains and the known waning immunity from vaccines. All individuals who are moderately to severely immunocompromised (including those with RA) should receive at least one additional vaccine dose compared to the general population. The ACIP has updated its recommendations for pneumococcal immunization, aiming to lower pneumococcal disease incidence in adults. Following the approval of the 21-valent pneumococcal conjugate vaccine, designed to target the serotypes commonly affecting adults, the cutoff for vaccination in the general population changed from \u2265\u200965 to \u2265\u200950 years. Recommendations for vaccination in RA patients (everyone age\u2009\u2265\u200918 years) remain unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Vaccine recommendations for RA patients constantly evolve as new DMARDs and vaccines are developed, and our understanding of their interaction with DMARDs vis a vis immunogenicity improves. It is essential to stay current with the latest recommendations from the ACIP and rheumatologic society guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-025-01197-6","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:43:49Z","timestamp":1758091429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vaccination Update and Specific Concerns for RA"],"prefix":"10.1007","volume":"27","author":[{"given":"Mariana","family":"Urquiaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"issue":"2","key":"1197_CR1","doi-asserted-by":"publisher","first-page":"e001041","DOI":"10.1136\/rmdopen-2019-001041","volume":"5","author":"V Furer","year":"2019","unstructured":"Furer V, Rondaan C, Heijstek M, Van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5(2):e001041.","journal-title":"RMD Open"},{"issue":"Si3","key":"1197_CR2","doi-asserted-by":"publisher","first-page":"Si242","DOI":"10.1093\/rheumatology\/kead246","volume":"62","author":"BR England","year":"2023","unstructured":"England BR. The Multimorbidity web in rheumatoid arthritis. Rheumatology (Oxford). 2023;62(Si3):Si242\u201351.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1197_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/acr.24831","volume":"74","author":"Y Wang","year":"2022","unstructured":"Wang Y, D\u2019Silva KM, Jorge AM, Li X, Lyv H, Wei J, et al. Increased risk of COVID-19 in patients with rheumatoid arthritis: A general Population-Based cohort study. Arthritis Care Res (Hoboken). 2022;74(5):741\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"1197_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3899\/jrheum.220986","volume":"50","author":"D Singer","year":"2023","unstructured":"Singer D, Thompson-Leduc P, Poston S, Gupta D, Cheng WY, Ma S, et al. Incidence of herpes Zoster in patients with rheumatoid arthritis in the united states: A retrospective cohort study. J Rheumatol. 2023;50(7):873\u201380.","journal-title":"J Rheumatol"},{"issue":"1","key":"1197_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41927-024-00431-5","volume":"8","author":"L Jin","year":"2024","unstructured":"Jin L, Gan J, Li X, Lu Y, Wang Y, Wong VKW. Rheumatoid arthritis and COVID-19 outcomes: a systematic review and Meta-analysis. BMC Rheumatol. 2024;8(1):61.","journal-title":"BMC Rheumatol"},{"issue":"1","key":"1197_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-017-1496-5","volume":"20","author":"LR Harrold","year":"2018","unstructured":"Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, et al. One-year risk of serious infection in patients treated with certolizumab Pegol as compared with other TNF inhibitors in a real-world setting: data from a National U.S. Rheumatoid arthritis registry. Arthritis Res Ther. 2018;20(1):2.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1197_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","volume":"77","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2018;77(6):905\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1197_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/rheumatology\/kex469","volume":"57","author":"S Subesinghe","year":"2018","unstructured":"Subesinghe S, Rutherford AI, Byng-Maddick R, Leanne Hyrich K, Benjamin Galloway J. Recurrent serious infections in patients with rheumatoid arthritis-results from the British society for rheumatology biologics register. Rheumatology (Oxford). 2018;57(4):651\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1197_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/annrheumdis-2021-221007","volume":"81","author":"IE Christensen","year":"2022","unstructured":"Christensen IE, Lillegraven S, Mielnik P, Bakland G, Loli L, Sexton J, et al. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. Ann Rheum Dis. 2022;81(3):398.","journal-title":"Ann Rheum Dis"},{"key":"1197_CR10","doi-asserted-by":"publisher","first-page":"1341321","DOI":"10.3389\/fimmu.2024.1341321","volume":"15","author":"N Mena-V\u00e1zquez","year":"2024","unstructured":"Mena-V\u00e1zquez N, Redondo-Rodriguez R, Rojas-Gimenez M, Romero-Barco CM, Fuego-Varela C, Perez-G\u00f3mez N, et al. Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study. Front Immunol. 2024;15:1341321.","journal-title":"Front Immunol"},{"issue":"8","key":"1197_CR11","doi-asserted-by":"publisher","first-page":"e0201799","DOI":"10.1371\/journal.pone.0201799","volume":"13","author":"A Wakabayashi","year":"2018","unstructured":"Wakabayashi A, Ishiguro T, Takaku Y, Miyahara Y, Kagiyama N, Takayanagi N. Clinical characteristics and prognostic factors of pneumonia in patients with and without rheumatoid arthritis. PLoS ONE. 2018;13(8):e0201799.","journal-title":"PLoS ONE"},{"issue":"1","key":"1197_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2474-13-158","volume":"13","author":"WA Blumentals","year":"2012","unstructured":"Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13(1):158.","journal-title":"BMC Musculoskelet Disord"},{"key":"1197_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1648-2","volume":"16","author":"E Backhaus","year":"2016","unstructured":"Backhaus E, Berg S, Andersson R, Ockborn G, Malmstr\u00f6m P, Dahl M, et al. Epidemiology of invasive Pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16:1\u201312.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"1197_CR14","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/acr.25028","volume":"75","author":"H Li","year":"2023","unstructured":"Li H, Wallace ZS, Sparks JA, Lu N, Wei J, Xie D, et al. Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: A general population study. Arthritis Care Res (Hoboken). 2023;75(5):956\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 1","key":"1197_CR15","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/infdis\/jiab040","volume":"226","author":"T Shi","year":"2022","unstructured":"Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: A systematic review and Meta-Analysis. J Infect Dis. 2022;226(Suppl 1):S17\u201321.","journal-title":"J Infect Dis"},{"key":"1197_CR16","doi-asserted-by":"crossref","unstructured":"Dlamini ST, Htet KM, Theint ECC, Mayadilanuari AM, Li WM, Tung YC et al. Herpes Zoster risk in patients with rheumatoid arthritis and its association with medications used. Int J Environ Res Public Health. 2023;20(3).","DOI":"10.3390\/ijerph20032123"},{"issue":"1","key":"1197_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Sch\u00e4fer M, et al. Risk of herpes Zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022;81(1):41\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"suppl5","key":"1197_CR18","doi-asserted-by":"publisher","first-page":"v26","DOI":"10.1093\/rheumatology\/kex523","volume":"57","author":"SC Kim","year":"2018","unstructured":"Kim SC, Feldman S, Moscicki AB. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology (Oxford). 2018;57(suppl5):v26\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"1197_CR19","doi-asserted-by":"crossref","unstructured":"Yang TO, Floud S, Reeves GK. Rheumatoid arthritis and cancer risk in the million women study. Int J Epidemiol. 2024;53(2).","DOI":"10.1093\/ije\/dyae006"},{"key":"1197_CR20","unstructured":"U.S. Centers for Disease Control and Prevention. Expanding Measles Outbreak in the United States and Guidance for the Upcoming Travel Season 2025 [Available from: https:\/\/www.cdc.gov\/han\/2025\/han00522.html"},{"key":"1197_CR21","unstructured":"U.S. Centers for Disease Control and Prevention. Measles Cases and Outbreaks 2025 [Available from: https:\/\/www.cdc.gov\/measles\/data-research\/index.html"},{"issue":"Suppl 1","key":"1197_CR22","first-page":"S27","volume":"189","author":"NJ Gay","year":"2004","unstructured":"Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis. 2004;189(Suppl 1):S27\u201335.","journal-title":"J Infect Dis"},{"issue":"4","key":"1197_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMcp1905181","volume":"381","author":"PM Strebel","year":"2019","unstructured":"Strebel PM, Orenstein WA, Measles. N Engl J Med. 2019;381(4):349\u201357.","journal-title":"N Engl J Med"},{"issue":"5","key":"1197_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.cmi.2019.08.022","volume":"26","author":"E Ben-Chetrit","year":"2020","unstructured":"Ben-Chetrit E, Oster Y, Jarjou\u2019i A, Megged O, Lachish T, Cohen MJ, et al. Measles-related hospitalizations and associated complications in jerusalem, 2018\u20132019. Clin Microbiol Infect. 2020;26(5):637\u201342.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"1197_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MD.0b013e3182a713c2","volume":"92","author":"C Rafat","year":"2013","unstructured":"Rafat C, Klouche K, Ricard JD, Messika J, Roch A, Machado S, et al. Severe measles infection: the spectrum of disease in 36 critically ill adult patients. Med (Baltim). 2013;92(5):257\u201372.","journal-title":"Med (Baltim)"},{"issue":"6","key":"1197_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","volume":"184","author":"MS Gebre","year":"2021","unstructured":"Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184(6):1589\u2013603.","journal-title":"Cell"},{"issue":"29","key":"1197_CR27","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1016\/j.vaccine.2018.06.004","volume":"36","author":"M Baay","year":"2018","unstructured":"Baay M, Bollaerts K, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. Vaccine. 2018;36(29):4207\u201314.","journal-title":"Vaccine"},{"key":"1197_CR28","unstructured":"U.S. Centers for Disease Control and Prevention. Adjuvants and Vaccines 2024 [Available from: https:\/\/www.cdc.gov\/vaccine-safety\/about\/adjuvants.html"},{"issue":"6","key":"1197_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Firestein GS. Rheumatoid Arthritis - Common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529\u201342.","journal-title":"N Engl J Med"},{"issue":"9","key":"1197_CR30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","volume":"10","author":"A Abhishek","year":"2022","unstructured":"Abhishek A, Boyton RJ, Peckham N, McKnight \u00c1, Coates LC, Bluett J, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med. 2022;10(9):840\u201350.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1197_CR31","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","volume":"81","author":"CSR Araujo","year":"2022","unstructured":"Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann Rheum Dis. 2022;81(6):889\u201397.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1197_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/annrheumdis-2021-221876","volume":"81","author":"ANA de Silva","year":"2022","unstructured":"de Silva ANA, Frommert LM, Albach FN, Klotsche J, Scholz V, Jeworowski LM, et al. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann Rheum Dis. 2022;81(6):881\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1197_CR33","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","volume":"80","author":"RH Haberman","year":"2021","unstructured":"Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1197_CR34","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1016\/S2665-9913(22)00228-4","volume":"4","author":"TG Skaria","year":"2022","unstructured":"Skaria TG, Sreeprakash A, Umesh R, Joseph S, Mohan M, Ahmed S, et al. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials. Lancet Rheumatol. 2022;4(11):e755\u201364.","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"1197_CR35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/annrheumdis-2013-203429","volume":"73","author":"MW Heijstek","year":"2014","unstructured":"Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman A-M, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014;73(8):1500\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1197_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","volume":"51","author":"S Adler","year":"2012","unstructured":"Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect of A\/H1N1 vaccination in immune-mediated disease\u2014a prospectively controlled vaccination study. Rheumatology. 2012;51(4):695\u2013700.","journal-title":"Rheumatology"},{"issue":"9","key":"1197_CR37","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","volume":"76","author":"JK Park","year":"2017","unstructured":"Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1559\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1197_CR38","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","volume":"77","author":"JK Park","year":"2018","unstructured":"Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77(6):898\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1197_CR39","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1136\/ard.2011.152983","volume":"70","author":"AC Ribeiro","year":"2011","unstructured":"Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70(12):2144\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1197_CR40","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/ard.2010.144451","volume":"70","author":"E Coulson","year":"2011","unstructured":"Coulson E, Saravanan V, Hamilton J, So KL, Morgan L, Heycock C, et al. Pneumococcal antibody levels after Pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70(7):1289\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"27\u201328","key":"1197_CR41","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1016\/j.vaccine.2008.04.028","volume":"26","author":"LB Gelinck","year":"2008","unstructured":"Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent Pneumococcal polysaccharide vaccine. Vaccine. 2008;26(27\u201328):3528\u201333.","journal-title":"Vaccine"},{"issue":"6","key":"1197_CR42","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.vaccine.2016.12.068","volume":"35","author":"MC Kapetanovic","year":"2017","unstructured":"Kapetanovic MC, Nagel J, Nordstr\u00f6m I, Saxne T, Geborek P, Rudin A. Methotrexate reduces vaccine-specific Immunoglobulin levels but not numbers of Circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate Pneumococcal vaccine. Vaccine. 2017;35(6):903\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"1197_CR43","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.1038\/s41598-021-88491-2","volume":"11","author":"P Nived","year":"2021","unstructured":"Nived P, Pettersson \u00c5, J\u00f6nsson G, Bengtsson AA, Settergren B, Skattum L, et al. Methotrexate reduces Circulating Th17 cells and impairs plasmablast and memory B cell expansions following Pneumococcal conjugate immunization in RA patients. Sci Rep. 2021;11(1):9199.","journal-title":"Sci Rep"},{"issue":"5","key":"1197_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/03009742.2020.1732459","volume":"49","author":"S Rasmussen","year":"2020","unstructured":"Rasmussen S, Fuursted K, Nielsen K, Laurberg N, S\u00f8rensen M, Fagerberg S, et al. Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status. Scand J Rheumatol. 2020;49(5):353\u201360.","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"1197_CR45","first-page":"952","volume":"34","author":"S Visvanathan","year":"2007","unstructured":"Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to Pneumococcal vaccine in patients with early rheumatoid arthritis receiving Infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34(5):952\u20137.","journal-title":"J Rheumatol"},{"issue":"10","key":"1197_CR46","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/art.40187","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, et al. The safety and immunogenicity of live Zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69(10):1969\u201377.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1197_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.42318","volume":"75","author":"JK Park","year":"2023","unstructured":"Park JK, Lee YJ, Shin K, Kang EH, Ha Y-J, Park JW, et al. A multicenter, prospective, randomized, Parallel-Group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis. Arthritis Rheumatol. 2023;75(2):171\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1197_CR48","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1197_CR49","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12891-017-1673-3","volume":"18","author":"H Wijesinghe","year":"2017","unstructured":"Wijesinghe H, Galappatthy P, de Silva R, Seneviratne SL, Saravanamuttu U, Udagama P, et al. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial. BMC Musculoskelet Disord. 2017;18(1):310.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"1197_CR50","doi-asserted-by":"publisher","first-page":"105464","DOI":"10.1016\/j.jbspin.2022.105464","volume":"90","author":"GSS C","year":"2023","unstructured":"C GSS, Sampaio-Barros MSRS, C PDJCBM, Gon\u00e7alves GS. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis. Joint Bone Spine. 2023;90(1):105464.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"1197_CR51","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41598-024-51535-4","volume":"14","author":"YK Kim","year":"2024","unstructured":"Kim YK, Choi Y, Jung JI, Kim JY, Kim MH, Curtis J, et al. Modeling of antibody responses to COVID-19 vaccination in patients with rheumatoid arthritis. Sci Rep. 2024;14(1):1335.","journal-title":"Sci Rep"},{"issue":"4","key":"1197_CR52","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/ard.2006.059881","volume":"66","author":"C Trollmo","year":"2007","unstructured":"Trollmo C, Gudmundsson S, Feltelius N, Rogberg S, Smedeg\u00e5rd G, Klareskog L. Sulphasalazine inhibits human antigen-specific immune responses in vivo. Ann Rheum Dis. 2007;66(4):481\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1197_CR53","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/rheumatology\/ker427","volume":"51","author":"EF Borba","year":"2012","unstructured":"Borba EF, Saad CG, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. Influenza A\/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology (Oxford). 2012;51(6):1061\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1197_CR54","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/ard.2005.043943","volume":"65","author":"A Holvast","year":"2006","unstructured":"Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006;65(7):913\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1197_CR55","doi-asserted-by":"publisher","first-page":"2318814","DOI":"10.1080\/21645515.2024.2318814","volume":"20","author":"KL Libardi Lira Machado","year":"2024","unstructured":"Libardi Lira Machado KL, da Costa-Rocha IA, Gon\u00e7alves Rodrigues Aguiar L, Ribeiro Moulaz I, Tatiyama Miyamoto S, Costa Martins P, et al. Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary sj\u00f6gren\u2019s syndrome. Hum Vaccin Immunother. 2024;20(1):2318814.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1197_CR56","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2021-221735","volume":"81","author":"AC Medeiros-Ribeiro","year":"2022","unstructured":"Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, da Silva HC, Saad CGS, et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Ann Rheum Dis. 2022;81(5):710\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1197_CR57","doi-asserted-by":"publisher","first-page":"e15013","DOI":"10.1111\/dth.15013","volume":"34","author":"K Pelka","year":"2021","unstructured":"Pelka K, Matyja-Bednarczyk A, Wojas-Pelc A, Pastuszczak M. Hydroxychloroquine does not impair antibody response to 13-valent Pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus-A pilot study. Dermatol Ther. 2021;34(4):e15013.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1197_CR58","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/acr.24824","volume":"74","author":"EFN Yuki","year":"2022","unstructured":"Yuki EFN, Borba EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, et al. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2022;74(4):562\u201371.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1197_CR59","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/ard.2005.036434","volume":"65","author":"I Fomin","year":"2006","unstructured":"Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65(2):191\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1197_CR60","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti\u2013tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and Pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2014;66(7):1016\u201326.","journal-title":"Arthritis Care Res"},{"key":"1197_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3047","volume":"12","author":"M Rehnberg","year":"2010","unstructured":"Rehnberg M, Brisslert M, Amu S, Zendjanchi K, H\u00e5wi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Therapy. 2010;12:1\u20138.","journal-title":"Arthritis Res Therapy"},{"issue":"10","key":"1197_CR62","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.medcli.2019.02.003","volume":"153","author":"P Richi","year":"2019","unstructured":"Richi P, Mart\u00edn MD, Nav\u00edo MT, Gonz\u00e1lez-Hombrado L, Salido M, Llorente J, et al. Antibody responses to influenza vaccine in patients on biological therapy: results of RIER cohort study. Medicina Cl\u00ednica. 2019;153(10):380\u20136.","journal-title":"Medicina Cl\u00ednica"},{"issue":"2","key":"1197_CR63","first-page":"272","volume":"34","author":"JL Kaine","year":"2007","unstructured":"Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and Pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34(2):272\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"1197_CR64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","volume":"45","author":"MC Kapetanovic","year":"2006","unstructured":"Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to Pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology. 2006;45(1):106\u201311.","journal-title":"Rheumatology"},{"issue":"20","key":"1197_CR65","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1016\/j.vaccine.2023.03.065","volume":"41","author":"M Frodlund","year":"2023","unstructured":"Frodlund M, Nived P, Chatzidionysiou A, S\u00f6dergren A, Klingberg E, Bengtsson A, et al. The impact of Immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA). Vaccine. 2023;41(20):3247\u201357.","journal-title":"Vaccine"},{"issue":"11","key":"1197_CR66","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.7326\/M20-6928","volume":"174","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Cofield SS, Bridges SL Jr., Bassler J, Deodhar A, Ford TL, et al. The safety and Immunologic effectiveness of the live Varicella-Zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: A randomized controlled trial. Ann Intern Med. 2021;174(11):1510\u20138.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1197_CR67","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1097\/MIB.0b013e318281341b","volume":"19","author":"DL Jacobson","year":"2013","unstructured":"Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1441\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1197_CR68","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.crohns.2013.09.022","volume":"8","author":"CK Lee","year":"2014","unstructured":"Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, et al. Patients with crohn\u2019s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent Pneumococcal polysaccharide vaccine. J Crohns Colitis. 2014;8(5):384\u201391.","journal-title":"J Crohns Colitis"},{"key":"1197_CR69","doi-asserted-by":"crossref","unstructured":"Hitchon CA, Bowdish DME, Boire G, Fortin PR, Flamand L, Chandran V et al. Methotrexate and tumor necrosis factor inhibitors independently decrease neutralizing antibodies after SARS-CoV-2 vaccination: updated results from the SUCCEED study. Vaccines (Basel). 2024;12(9).","DOI":"10.3390\/vaccines12091061"},{"issue":"10","key":"1197_CR70","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","volume":"70","author":"NA Kennedy","year":"2021","unstructured":"Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884\u201393.","journal-title":"Gut"},{"key":"1197_CR71","doi-asserted-by":"crossref","unstructured":"Rabinowitz KM, Navon M, Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Goren I et al. Anti-TNF\u03b1 treatment impairs Long-Term immune responses to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases. Vaccines (Basel). 2022;10(8).","DOI":"10.3390\/vaccines10081186"},{"issue":"26","key":"1197_CR72","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1016\/j.vaccine.2023.05.012","volume":"41","author":"F Bordalo Ferreira","year":"2023","unstructured":"Bordalo Ferreira F, Rafael MA, Coimbra L, Boavida N, Arrobas F, Pereira Correia F, et al. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease. Vaccine. 2023;41(26):3862\u201371.","journal-title":"Vaccine"},{"issue":"8","key":"1197_CR73","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","volume":"29","author":"U Arad","year":"2011","unstructured":"Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643\u20138.","journal-title":"Vaccine"},{"key":"1197_CR74","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s10067-019-04439-y","volume":"38","author":"K Lakota","year":"2019","unstructured":"Lakota K, Perdan-Pirkmajer K, Sodin-\u0160emrl S, \u010cu\u010dnik S, \u0160ubelj V, Prosenc K, et al. The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients\u2014a 6-month follow-up prospective study. Clin Rheumatol. 2019;38:1277\u201392.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"1197_CR75","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard.2007.077461","volume":"67","author":"S Oren","year":"2008","unstructured":"Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1197_CR76","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S Van Assen","year":"2010","unstructured":"Van Assen S, Holvast A, Benne CA, Posthumus MD, Van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheumatism: Official J Am Coll Rheumatol. 2010;62(1):75\u201381.","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"1","key":"1197_CR77","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"IIICO Bingham","year":"2010","unstructured":"Bingham IIICO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheumatism: Official J Am Coll Rheumatol. 2010;62(1):64\u201374.","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"5","key":"1197_CR78","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1186\/ar4358","volume":"15","author":"M Crnkic Kapetanovic","year":"2013","unstructured":"Crnkic Kapetanovic M, Saxne T, J\u00f6nsson G, Truedsson L, Geborek P. Rituximab and abatacept but not Tocilizumab impair antibody response to Pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171.","journal-title":"Arthritis Res Ther"},{"key":"1197_CR79","first-page":"1","volume":"22","author":"P Nived","year":"2020","unstructured":"Nived P, J\u00f6nsson G, Settergren B, Einarsson J, Olofsson T, J\u00f8rgensen CS, et al. Prime-boost vaccination strategy enhances immunogenicity compared to single Pneumococcal conjugate vaccination in patients receiving conventional dmards, to some extent in abatacept but not in rituximab-treated patients. Arthritis Res Therapy. 2020;22:1\u201312.","journal-title":"Arthritis Res Therapy"},{"issue":"6","key":"1197_CR80","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/art.42058","volume":"74","author":"S Bitoun","year":"2022","unstructured":"Bitoun S, Henry J, Desjardins D, Vauloup-Fellous C, Dib N, Belkhir R, et al. Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol. 2022;74(6):927\u201333.","journal-title":"Arthritis Rheumatol"},{"key":"1197_CR81","doi-asserted-by":"crossref","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. MedRxiv. 2021.","DOI":"10.1101\/2021.04.05.21254656"},{"issue":"6","key":"1197_CR82","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/art.30325","volume":"63","author":"C Gabay","year":"2011","unstructured":"Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of synthetic and biologic disease\u2010modifying antirheumatic drugs on antibody responses to the AS03\u2010adjuvanted pandemic influenza vaccine: a prospective, open\u2010label, parallel\u2010cohort, single\u2010center study. Arthr Rhuem. 2011;63(6):1486\u201396.","journal-title":"Arthr Rhuem"},{"issue":"1","key":"1197_CR83","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/cei.12390","volume":"178","author":"J Westra","year":"2014","unstructured":"Westra J, Van Assen S, Wilting K, Land J, Horst G, De Haan A, et al. Rituximab impairs Immunoglobulin (Ig) M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Experimental Immunol. 2014;178(1):40\u20137.","journal-title":"Clin Experimental Immunol"},{"key":"1197_CR84","doi-asserted-by":"crossref","unstructured":"Venerito V, Stefanizzi P, Cantarini L, Lavista M, Galeone MG, Di Lorenzo A et al. Immunogenicity and safety of adjuvanted Recombinant Zoster vaccine in rheumatoid arthritis patients on Anti-Cellular biologic agents or JAK inhibitors: A prospective observational study. Int J Mol Sci. 2023;24(8).","DOI":"10.3390\/ijms24086967"},{"issue":"1","key":"1197_CR85","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.1093\/cid\/ciab954","volume":"75","author":"N Madelon","year":"2022","unstructured":"Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, et al. Robust T-Cell responses in Anti-CD20-Treated patients following COVID-19 vaccination: A prospective cohort study. Clin Infect Dis. 2022;75(1):e1037\u201345.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1197_CR86","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","volume":"80","author":"D Mrak","year":"2021","unstructured":"Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;80(10):1345\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1197_CR87","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/acr.21838","volume":"65","author":"AC Ribeiro","year":"2013","unstructured":"Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, et al. Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):476\u201380.","journal-title":"Arthritis Care Res"},{"key":"1197_CR88","doi-asserted-by":"crossref","unstructured":"Winthrop KHJ, Weinberg A, Siegel S, Baxter J, Garth K, Huffstutter J, Loveless J, gharib S, Reddy S, Sinha J, Moreta E, Ridley D, Messaoudi I, Curtis J. Immunogenicity of the Recombinant Zoster vaccine in people with rheumatoid arthritis using abatacept [abstract]. Arthritis Rheumatol. 2024;(76 (suppl 9)).","DOI":"10.1136\/annrheumdis-2024-eular.979"},{"key":"1197_CR89","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12891-016-1082-z","volume":"17","author":"R Alten","year":"2016","unstructured":"Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, et al. Antibody response to Pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016;17:231.","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"1197_CR90","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/ar2174","volume":"9","author":"L Tay","year":"2007","unstructured":"Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent Pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther. 2007;9(2):R38.","journal-title":"Arthritis Res Ther"},{"key":"1197_CR91","unstructured":"Mudano ACG, Holladay E, Winthrop K, Mikuls T, Thiele G, Law M, Bastidas M, Zikry M, Chun K, George M, Sinha J, Alvarez N, Tesser J, Curtis J. Randomization to holding versus continuing (JAKi, IL17) and autoimmune patient responses to COVID-19 boosters: results from the Covid-19 vaccine response in rheumatology patients (COVER) study [abstract]. Arthritis Rheumatol. 2024;76."},{"issue":"3","key":"1197_CR92","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/14397595.2013.843743","volume":"24","author":"T Tsuru","year":"2014","unstructured":"Tsuru T, Terao K, Murakami M, Matsutani T, Suzaki M, Amamoto T, et al. Immune response to influenza vaccine and Pneumococcal polysaccharide vaccine under IL-6 signal Inhibition therapy with Tocilizumab. Mod Rheumatol. 2014;24(3):511\u20136.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"1197_CR93","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","volume":"71","author":"S Mori","year":"2012","unstructured":"Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of Tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(12):2006\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1197_CR94","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","volume":"74","author":"CO Bingham","year":"2015","unstructured":"Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1197_CR95","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202658","volume":"72","author":"S Mori","year":"2013","unstructured":"Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving Tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1197_CR96","doi-asserted-by":"crossref","unstructured":"Bindoli S, Baggio C, Galozzi P, Vesentini F, Doria A, Cosma C et al. Autoinflammatory diseases and COVID-19 vaccination: analysis of SARS-CoV-2 Anti-S-RBD IgG levels in a cohort of patients receiving IL-1 inhibitors. J Clin Med. 2023;12(14).","DOI":"10.3390\/jcm12144741"},{"key":"1197_CR97","doi-asserted-by":"crossref","unstructured":"Geck L, Tascilar K, Simon D, Kleyer A, Schett G, Rech J. Anti-Interleukin-1 therapy does not affect the response to SARS-CoV-2 vaccination and infection in patients with systemic autoinflammatory diseases. J Clin Med. 2023;12(24).","DOI":"10.3390\/jcm12247587"},{"issue":"4","key":"1197_CR98","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of Tofacitinib on Pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1197_CR99","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/rheumatology\/keab879","volume":"61","author":"L Iancovici","year":"2022","unstructured":"Iancovici L, Khateeb D, Harel O, Peri R, Slobodin G, Hazan Y, et al. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology (Oxford). 2022;61(8):3439\u201347.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1197_CR100","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s10067-022-06329-2","volume":"41","author":"A Sch\u00e4fer","year":"2022","unstructured":"Sch\u00e4fer A, Kovacs MS, Eder A, Nigg A, Feuchtenberger M. Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis. Clin Rheumatol. 2022;41(12):3707\u201314.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1197_CR101","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1093\/rheumatology\/keae584","volume":"64","author":"C Sieiro Santos","year":"2025","unstructured":"Sieiro Santos C, Herrero JG, Ordas Mart\u00ednez J, \u00c1lvarez Castro C, L\u00f3pez Robles A, Colindres R, et al. Immunogenicity to herpes Zoster Recombinant subunit vaccine in immune-mediated rheumatic patients under treatment with JAK inhibitors. Rheumatology (Oxford). 2025;64(5):2442\u201350.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1197_CR102","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ajh.26388","volume":"97","author":"E Muchtar","year":"2022","unstructured":"Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, et al. Humoral and cellular immune responses to Recombinant herpes Zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022;97(1):90\u20138.","journal-title":"Am J Hematol"},{"issue":"3","key":"1197_CR103","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/art.42386","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023;75(3):333\u201348.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1197_CR104","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/art.42372","volume":"75","author":"JR Curtis","year":"2023","unstructured":"Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol. 2023;75(1):E1\u201316.","journal-title":"Arthritis Rheumatol"},{"key":"1197_CR105","unstructured":"U.S. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States 2025 [Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#table-01"},{"key":"1197_CR106","unstructured":"U.S. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) 2025 [Available from: https:\/\/www.cdc.gov\/acip\/index.html"},{"issue":"5","key":"1197_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","volume":"73","author":"LA Grohskopf","year":"2024","unstructured":"Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization Practices - United states, 2024-25 influenza season. MMWR Recomm Rep. 2024;73(5):1\u201325.","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"1197_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","volume":"74","author":"M Kobayashi","year":"2025","unstructured":"Kobayashi M, Leidner AJ, Gierke R, Xing W, Accorsi E, Moro P, et al. Expanded recommendations for use of Pneumococcal conjugate vaccines among adults aged\u2009\u2265\u200950 years: recommendations of the advisory committee on immunization Practices - United states, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"37","key":"1197_CR109","doi-asserted-by":"publisher","first-page":"819","DOI":"10.15585\/mmwr.mm7337e2","volume":"73","author":"L Panagiotakopoulos","year":"2024","unstructured":"Panagiotakopoulos L, Moulia DL, Godfrey M, Link-Gelles R, Roper L, Havers FP, et al. Use of COVID-19 vaccines for persons aged\u2009\u2265\u20096 months: recommendations of the advisory committee on immunization Practices - United states, 2024\u20132025. MMWR Morb Mortal Wkly Rep. 2024;73(37):819\u201324.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1197_CR110","doi-asserted-by":"crossref","unstructured":"Lauren E, Roper MG, Ruth Link-Gelles DL, Moulia CA, Taylor G, Peacock N, Brewer O, Brooks G, Kuchel H, Keipp Talbot R, Schechter KE. Fleming-Dutra, Lakshmi panagiotakopoulos. Use of additional doses of 2024\u20132025 COVID-19 vaccine for adults aged\u2009\u2265\u200965 years and persons aged\u2009\u2265\u20096 months with moderate or severe immunocompromise: recommendations of the advisory committee on immunization Practices \u2014 United states, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(49):1118\u201323.","DOI":"10.15585\/mmwr.mm7349a2"},{"key":"1197_CR111","doi-asserted-by":"crossref","unstructured":"Curtis JCD, Krueger W, Gara A, Winthrop K. Use of the shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes Zoster [abstract]. Arthritis Rheumatol. 2024;76 (suppl 9).","DOI":"10.1186\/s13075-025-03565-0"},{"issue":"3","key":"1197_CR112","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","volume":"71","author":"TC Anderson","year":"2022","unstructured":"Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, et al. Use of Recombinant Zoster vaccine in immunocompromised adults aged\u2009\u2265\u200919 years: recommendations of the advisory committee on immunization Practices - United states, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1197_CR113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2012.7304","volume":"308","author":"J Zhang","year":"2012","unstructured":"Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes Zoster and risk of herpes Zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43\u20139.","journal-title":"JAMA"},{"issue":"32","key":"1197_CR114","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","volume":"68","author":"E Meites","year":"2019","unstructured":"Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698\u2013702.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"1197_CR115","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","volume":"73","author":"A Britton","year":"2024","unstructured":"Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, et al. Use of respiratory syncytial virus vaccines in adults aged\u2009\u2265\u200960 years: updated recommendations of the advisory committee on immunization Practices - United states, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696\u2013702.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1197_CR116","doi-asserted-by":"crossref","unstructured":"Ricc\u00f2 M, Cascio A, Corrado S, Bottazzoli M, Marchesi F, Gili R et al. Efficacy of respiratory syncytial virus vaccination to prevent lower respiratory tract illness in older adults: A systematic review and Meta-Analysis of randomized controlled trials. Vaccines (Basel). 2024;12(5).","DOI":"10.3390\/vaccines12050500"},{"issue":"46","key":"1197_CR117","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.15585\/mmwr.mm7146a1","volume":"71","author":"E Krow-Lucal","year":"2022","unstructured":"Krow-Lucal E, Marin M, Shepersky L, Bahta L, Loehr J, Dooling K, Measles. Mumps, Rubella vaccine (PRIORIX): recommendations of the advisory committee on immunization Practices - United states, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(46):1465\u201370.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"1197_CR118","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1136\/ard.2006.063586","volume":"66","author":"MW Heijstek","year":"2007","unstructured":"Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and Rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1197_CR119","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","volume":"38","author":"Y Uziel","year":"2020","unstructured":"Uziel Y, Moshe V, Onozo B, Kulcs\u00e1r A, Tr\u00f3bert-Sipos D, Akikusa JD, et al. Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. Vaccine. 2020;38(9):2198\u2013201.","journal-title":"Vaccine"},{"key":"1197_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-018-0235-z","volume":"16","author":"J Jeyaratnam","year":"2018","unstructured":"Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, et al. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatr Rheumatol. 2018;16:1\u20136.","journal-title":"Pediatr Rheumatol"},{"issue":"Rr\u201304","key":"1197_CR121","first-page":"1","volume":"62","author":"HQ McLean","year":"2013","unstructured":"McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, Rubella, congenital Rubella syndrome, and mumps, 2013: summary recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2013;62(Rr\u201304):1\u201334.","journal-title":"MMWR Recomm Rep"},{"key":"1197_CR122","unstructured":"U.S. Centers for Disease Control and Prevention. Measles Vaccine Recommendations 2025 [Available from: https:\/\/www.cdc.gov\/measles\/hcp\/vaccine-considerations\/index.html"},{"key":"1197_CR123","unstructured":"Ruth Jessen Hickman M. Measles Is Back. How Does This Affect Patients with Rheumatic Disease? The Rheumatologist. 2019;2019."},{"key":"1197_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-020-00479-w","volume":"18","author":"IHR Grein","year":"2020","unstructured":"Grein IHR, Pinto NBF, Groot N, Martins CB, Lobo A, Aikawa NE, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study. Pediatr Rheumatol. 2020;18:1\u201312.","journal-title":"Pediatr Rheumatol"},{"issue":"11","key":"1197_CR125","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","volume":"51","author":"IL Fran\u00e7a","year":"2012","unstructured":"Fran\u00e7a IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford). 2012;51(11):2091\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1197_CR126","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","volume":"46","author":"MC Kapetanovic","year":"2007","unstructured":"Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2007;46(4):608\u201311.","journal-title":"Rheumatology (Oxford)"},{"key":"1197_CR127","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s13075-015-0863-3","volume":"17","author":"K Migita","year":"2015","unstructured":"Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Effect of abatacept on the immunogenicity of 23-valent Pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17:357.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1197_CR128","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12916-023-02868-w","volume":"21","author":"F Filippini","year":"2023","unstructured":"Filippini F, Giacomelli M, Bazzani C, Fredi M, Semeraro P, Tomasi C, et al. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response. BMC Med. 2023;21(1):210.","journal-title":"BMC Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01197-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-025-01197-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01197-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:04:50Z","timestamp":1770750290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-025-01197-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1007\/s11926-025-01197-6","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"9 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KLW has received honoraria or grant funds from UCB, Abbvie, Galapagos, Lilly, BMS, GSK, Regeneron, Sanofi, Roche, and Genentech. JRC has received honoraria or consulting and research studies fees from Abbvie, Amgen, BMS, GSK, Janssen, Lilly, Novartis, Pfizer, Sanofi, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"37"}}